ClinicalTrials.Veeva

Menu

Trigeminal Nerve Stimulation of the Treatment of Epilepsy

Baylor College of Medicine logo

Baylor College of Medicine

Status

Active, not recruiting

Conditions

Epilepsy (Treatment Refractory)

Treatments

Device: Trigeminal nerve stimulation

Study type

Interventional

Funder types

Other
Other U.S. Federal agency

Identifiers

NCT07220161
H-55827

Details and patient eligibility

About

Background: Epilepsy is a common neurological disorder among veterans. Medications do not control seizures in 1/3rd of patients, who often require neurostimulation. However, current neurostimulation devices are invasive. Objective: The investigators propose a novel clinical trial to repurpose the FDA-approved Cefaly device, designed for migraine relief, to treat epilepsy. The Cefaly device works by non-invasive Trigeminal neurostimulation (TNS). TNS has previously shown promising preliminary results in seizure improvement. Design: The investigators will engage 24 veterans with drug-resistant epilepsy, half of whom will receive standard care, while the other half will receive standard care plus Cefaly. This will be followed by a crossover of the treatment/control groups. The primary objective is to evaluate seizure frequency improvement over 12 months.

Enrollment

24 estimated patients

Sex

Male

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adults age 18 to 65 years of age at time of consent
  • Subject must have a confirmed diagnosis of epilepsy of at least 1 year, specified as focal onset epilepsy.
  • Focal epilepsy with motor signs
  • A minimum seizure frequency of one seizure over a 4-week period
  • Subject must have failed to achieve seizure control with at least two appropriate antiseizure medications (ASM) based on the 2009 ILAE definition of drug resistant epilepsy
  • Current treatment with at least 1 ASM with stable doses for at least three months

Exclusion criteria

  • Any condition that would impact a subject's ability to follow study procedures or subject's safety
  • History of significant adverse reactions to electrical stimulation (e.g. TEMS device)
  • Subjects with only focal aware nonmotor seizures
  • Women of childbearing age, pregnant or breastfeeding
  • Implanted cardiac pacemaker or implanted/wearable defibrillator or implanted metallic device in head

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

24 participants in 2 patient groups

Treatment with Trigeminal Nerve Stimulation
Experimental group
Description:
Treatment with trigeminal nerve stimulation x 6 months
Treatment:
Device: Trigeminal nerve stimulation
Control
No Intervention group
Description:
Standard care x 6 months

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems